Get notified when MLTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $14.54 Per Share (new) — New investors pay $20.00 per share for a company with net tangible book value of only $5.70 per share after the offering, a 71% dilution.
- Pfic Risk (new) — The company may be classified as a passive foreign investment company, which would impose burdensome tax reporting and potentially higher taxes on U.S. investors.
MoonLake Immunotherapeutics prices $200M offering of 9M shares plus pre-funded warrants at $20.00/share
Filed June 24, 2026 · ~1 min read
Key Changes
-
high
MoonLake is selling 9,000,000 Class A Ordinary Shares at $20.00 per share, plus pre-funded warrants for up to 1,000,000 shares, raising approximately $188.8 million net to the company.
The Offering verify on EDGAR → -
high
Net proceeds of $188.8 million will fund development and pre-commercialization of SLK, its lead candidate for hidradenitis suppurativa, with cash runway expected to mid-2028.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $14.54 per share, as the as-adjusted net tangible book value after the offering is only $5.70 per share.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Partner
Trade MLTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify